IMPROVING BREAST CANCER OUTCOMES BY OVERCOMING RESISTANCE TO CDK4/6 INHIBITORS
Grant number: 1177357 | Funding period: 2020 - 2024
Related publications (3)
Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation.
Max Heckler, Lestat R Ali, Eleanor Clancy-Thompson, Li Qiang, Katherine S Ventre, Patrick Lenehan, Kevin Roehle, Adrienne Luoma, Kelly Boelaars, Vera Peters, Julia McCreary, Tamara Boschert, Eric S Wang, Shengbao Suo, Francesco Marangoni, Thorsten R Mempel, Henry W Long, Kai W Wucherpfennig, Michael Dougan, Nathanael S Gray
CDK4/6 inhibitors are approved to treat breast cancer and are in trials for other malignancies. We examined CDK4/6 inhibition in m..
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
Laura M Spring, Shealagh L Clark, Tianyu Li, Shom Goel, Nabihah Tayob, Elene Viscosi, Elizabeth Abraham, Dejan Juric, Steven J Isakoff, Erica Mayer, Beverly Moy, Jeffrey G Supko, Sara M Tolaney, Aditya Bardia
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additi..
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity
April C Watt, Paloma Cejas, Molly J DeCristo, Otto Metzger-Filho, Enid YN Lam, Xintao Qiu, Haley BrinJones, Nikolas Kesten, Rhiannon Coulson, Alba Font-Tello, Klothilda Lim, Raga Vadhi, Veerle W Daniels, Joan Montero, Len Taing, Clifford A Meyer, Omer Gilan, Charles C Bell, Keegan D Korthauer, Claudia Giambartolomei
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) were designed to induce cancer cell cycle arrest. Recent stu..